Marksans Pharma Q1 FY27: Revenue ₹841cr, PAT ₹159cr

Strong start to FY27, but expectations stayed high

Marksans Pharma Limited (NSE: MARKSANS) reported its strongest first quarter on record for FY27, supported by broad-based growth across key markets. Consolidated operating revenue for Q1 FY27 stood at ₹840.8 crore, up 35.6% year-on-year from ₹620.0 crore. The company also reported its highest-ever quarterly EBITDA at ₹213.0 crore and profit after tax (PAT) at ₹159.4 crore. Cash balances crossed the ₹1,000 crore mark for the first time, ending the quarter at ₹1,058 crore. Despite the record profitability, the stock fell 3.07% to ₹303.40 after the results, with commentary pointing to a revenue miss versus analyst expectations.

Key Q1 numbers: revenue, margins, and profit records

The June 2026 quarter delivered a step-up in profitability, with operating leverage visible in margins. Gross margin expanded to 59.1%, up 138 basis points year-on-year from 57.8%. Gross profit was reported at ₹497.3 crore, up 38.9% year-on-year from ₹358.2 crore. EBITDA more than doubled to ₹213.0 crore versus ₹100.1 crore in Q1 FY26, translating to 112.8% growth. EBITDA margin rose to 25.3% from 16.1%, an improvement of 919 basis points. PAT rose to ₹159.4 crore, up 173.9% year-on-year, with PAT margin at 18.4% versus 9.3% a year earlier.

Geography mix: North America steady, Europe surges

North America remained Marksans Pharma’s largest market in the quarter. Revenue from North America was ₹377 crore, up 15.1% year-on-year, and represented about 45% of consolidated revenue. UK and Europe delivered the biggest growth, with revenue of ₹356 crore, up 74.7% year-on-year and described as the highest-ever quarterly level. The company’s disclosures included around ₹44 crore from the QliniQ B.V. acquisition within the UK and Europe number. ANZ revenue was ₹88 crore, up 53.7% year-on-year, with management linking sequential moderation to seasonality after a strong prior quarter. Rest of World contributed ₹20 crore, with the company citing war-related transportation disruptions.

What drove the margin expansion

Marksans Pharma attributed gross margin gains to a favourable product mix and lower-cost inventory. The company also pointed to foreign exchange tailwinds in its commentary on gross margin improvement. On a quarter-on-quarter basis, the gross margin improvement was described as 478 basis points. The EBITDA margin expansion was also linked to operating leverage, with costs growing slower than revenues in the quarter. Higher scale in key markets, especially UK and Europe, contributed to the consolidated improvement. The results were presented as a combination of growth and efficiency, reflected in record quarterly EBITDA and PAT.

Cash build-up and working capital movement

The company ended Q1 FY27 with a cash balance of ₹1,058 crore, compared with ₹711 crore at the end of Q1 FY26. Net cash was reported at ₹1,031 crore. Management highlighted that this was achieved despite payments made during the quarter towards the QliniQ acquisition. Cash from operations stood at ₹185 crore. Free cash flow was reported at ₹152 crore after net capex of ₹33 crore. Working capital cycle improved to about 132 days, from about 159 days year-on-year and about 138 days sequentially.

Integration in Europe and FY27 focus areas

Marksans Pharma said integration of QliniQ B.V. and ABCnow GmbH was successful. The company also outlined plans to expand further in Europe. A revenue target of EUR 180 million for FY 2027 was mentioned in the context of the Europe expansion efforts. The quarter’s UK and Europe performance already reflected acquisition-led contribution, alongside strong growth even excluding acquisitions. Management’s comments positioned Europe as a major driver of near-term growth. The company also flagged that some markets can see seasonal patterns, including a mention of summer-related softness expected to reverse in North America.

R&D and product strategy signals

R&D spend in Q1 FY27 was ₹23.2 crore, or 2.8% of revenue, compared with 2.0% in the year-ago quarter. The company linked this spending to a focus on differentiated dosage forms. While the quarter’s headline numbers were driven by scale and mix, the R&D line suggested continued investment in portfolio development. Higher profitability helped accommodate incremental R&D without pressuring margins. The disclosures did not provide product-level breakouts, but the mix benefit was explicitly cited. Investors typically track this line for sustainability of launches and competitiveness over time.

Market reaction and why it mattered

The company’s record EBITDA and PAT were accompanied by a negative stock reaction on the results day. Shares fell 3.07% to ₹303.40 following the presentation, with commentary pointing to revenue coming in below analyst expectations. The move underscored that markets can focus on the gap between reported revenue and forecasts, even when profit metrics hit records. At the same time, the quarter showed strong cash generation and balance sheet strength, with cash crossing ₹1,000 crore. Europe’s sharp growth and integration progress were key positives in the operating narrative. The results were discussed on the earnings call hosted by DAM Capital Advisors Limited on August 13, 2026, following the results declaration on August 12, 2026.

Snapshot table: Q1 FY27 reported metrics

Conclusion

Marksans Pharma’s Q1 FY27 showed sharp year-on-year growth in revenue and a larger jump in profitability, with record EBITDA and PAT and a stronger cash position. The quarter also highlighted Europe as the fastest-growing region, supported by the integration of QliniQ B.V. and ABCnow GmbH. While the stock fell after the results amid a revenue miss versus expectations, the company’s reported metrics pointed to improving margins and cash generation. Investors are likely to track the sustainability of margin gains, working capital discipline, and the pace of Europe expansion. The company has already articulated a Europe revenue target of EUR 180 million for FY 2027, setting a clear milestone for subsequent quarters.